anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-30. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
== External links == Jeffries WB (1999-02-17). "Inverse Agonists for Medical Students". Office of Medical Education - Courses - IDC 105 Principles of Pharmacology. Creighton University School of Medicine - Department of Pharmacology. Retrieved 2008-08-12. Inverse Agonists: An Illustrated Tutorial Panesar K, Guzman F. Pharmacology Corner. 2012
== Misattributed == Teleny, or The Reverse of the Medal (Paris, 1893) has been attributed to Wilde, but its authorship is unclear. One theory is that it was a combined effort by several of Wilde's friends, which he may have edited. Constance – On September 14, 2011, Wilde's grandson Merlin Holland contested Wilde's claimed authorship of this play entitled Constance, scheduled to open that week in the King's Head Theatre. It was not, in fact, "Oscar Wilde's final play," as its producers were claiming. Holland said Wilde did sketch out the play's scenario in 1894, but "never wrote a word" of it, and that "it is dishonest to foist this on the public." The artistic director Adam Spreadbury-Maher of the King's Head Theatre and producer of Constance pointed out that Wilde's son, Vyvyan Holland, wrote, in 1954, "a significant amount of the dialogue (of Constance) bears the authentic stamp of my father's hand". There is further proof that the developed scenario that Constance was reconstituted from was written by Wilde between 1897 and his death in 1900, rather than the 1894 George Alexander scenario which Merlin Holland quotes.
Eddy tried every remedy for her ill health, including a three-month stay at the Vail's Hydropathic Institute in Hill, New Hampshire. She told the Boston Post in 1883 that, for the seven years prior to 1862 (most of her second marriage), she had been effectively confined to her bed or room. In 1861 Eddy heard of a healing method developed by Phineas Parkhurst Quimby, a former clockmaker in Portland, Maine. Self-styled Dr. P. P. Quimby, a practitioner of the "Science of Health," had become interested in healing after recovering suddenly from a condition he believed was consumption (tuberculosis). After attending a lecture in Maine in 1837 by the French mesmerist Charles Poyen, Quimby began to practice mesmerism himself. Mesmerism was named after Franz Mesmer (1734–1815), a German physician who argued for the existence of a fluid through which bodies could influence each other, a force he called animal magnetism. Quimby and an assistant, Lucius Burkmar, traveled around Maine and New Brunswick giving demonstrations; Burkmar, in a trance, would offer mind readings and suggestions for cures. Quimby abandoned mesmerism around 1847 when he realized that it was suggestion that was effecting the apparent cures. He came to the view that disease was a mental state. When Jesus healed a paralysed arm, he had known, Quimby wrote, "that the arm was not the cause but the effect, and he addressed Himself to the intelligence, and applied His wisdom to the cause".
Sources: en.wikipedia.org
As numerous ASSRs declared sovereignty and self-promotion to Soviet Socialist Republics, Art. 71 and 72 of the Constitution of the RSFSR were amended on May 24, 1991 to recognize its autonomous republics as SSRs; it was further amended on July 3 to promote all its autonomous oblasts other than Jewish Autonomous Oblast to SSRs. This decision came into conflict with Art. 85 of the Constitution of the USSR.
The major components of an MRI scanner are the main magnet, which polarizes the sample, the shim coils for correcting shifts in the homogeneity of the main magnetic field, the gradient system which is used to localize the region to be scanned and the RF system, which excites the sample and detects the resulting NMR signal. The whole system is controlled by one or more computers. In most medical applications, hydrogen nuclei, which consist solely of a proton, that are in tissues create a signal that is processed to form an image of the body in terms of the density of those nuclei in a specific region. Given that the protons are affected by fields from other atoms to which they are bonded, it is possible to separate responses from hydrogen in specific compounds. To perform a study, the person is positioned within an MRI scanner that forms a strong magnetic field around the area to be imaged. First, energy from an oscillating magnetic field is temporarily applied to the patient at the appropriate resonance frequency. Scanning with X and Y gradient coils causes a selected region of the patient to experience the exact magnetic field required for the energy to be absorbed. The atoms are excited by a RF pulse and the resultant signal is measured by one or more receiving coils. The RF signal may be processed to deduce position information by looking at the changes in RF level and phase caused by varying the local magnetic field using gradient coils.
Monitoring the sky at 3, 10, 30, 100 and 300 microns, especially at 1, 3, and 10 mm, in order to identify one hundred of the most powerful sources among those observed and at each frequency; Study in detail the properties of quasars and other unusual objects; Search for monochromatic anomalies among the most powerful radio sources (such as a hydroxyl emission line), in the decimeter band; Search for periodic signals (pulsars) of interstellar origin, in the same band; Searches for monochromatic signals of different frequencies, always in the same band. According to Kardashev, only a radio interferometer with a base, either of the order of or larger than the diameter of the Earth, placed in orbital space, would allow listening to centimetric and decimetric frequencies. Once a set of unusual sources has been selected, the next step is to look for significant content in the radiations from these objects. In 1998, Nikolai Kardashev, S. F. Likhachev, and V. I. Zhuravlev proposed two SETI space projects to detect artificial sources: the Millimetron project (an orbiting observatory with a 10 m diameter mirror) and the VLBI optical telescope (for interferometric synthesis of ultraviolet, optical, and infrared images).
Sources: en.wikipedia.org
=== „Sozusagen Paris“ (2016) === „Sozusagen Paris“' (Paris, So to Speak) constitutes a sequel to the previous novel: after a public reading from „Love Writ Large“, the first-person narrator is approached by his childhood sweetheart, who is now the mayor of a small town. This sequel describes the first encounter between the two characters after thirty years, which lasts from the moment of their reunion after the public reading until the next morning. Overall, the text complements its predecessor: whereas the former dealt with the ecstasy of first love, the latter focuses on long-term love, specifically in light of Jutta's 23-year marriage. Whereas „Love Writ Large“ was told from the man's perspective, the nighttime conversation in Paris, So to Speak is shaped by the woman’s point of view —for the first time in Kermani's work, a female voice is at the center of the text. Like „Love Writ Large, Paris So to Speak“ also aims at a supra-individual exploration of love, but it is anchored differently: instead of early Islamic mysticism, it’s the French marriage novels of the nineteenth century up to Marcel Proust which serve as a foil here for modern love. This shifts the reflection on love from a general anthropological to a historical perspective. In particular, the important role of their children to the couple's life, lifestyle, and emotional stability serves to emphasize distinctions from older marriage novels and to highlight specifics of love and cohabitation in the 21st century.
A common substrate used in this type of system is glass. Depending if the system is open or closed, there would be either one or two layers of glass. The bottom layer of the device contains a patterned array of individually controllable electrodes. When looking at a closed system, there is usually a continuous ground electrode found through the top layer made usually of indium tin oxide (ITO). The dielectric layer is found around the electrodes in the bottom layer of the device and is important for building up charges and electrical field gradients on the device. A hydrophobic layer is applied to the top layer of the system to decrease the surface energy where the droplet will actually be in contact with. The applied voltage activates the electrodes and allows changes in the wettability of droplet on the device's surface. In order to move a droplet, a control voltage is applied to an electrode adjacent to the droplet, and at the same time, the electrode just under the droplet is deactivated. By varying the electric potential along a linear array of electrodes, electrowetting can be used to move droplets along this line of electrodes. Modifications to this foundation can also be fabricated into the basic design structure. One example of this is the addition of electrochemiluminescence detectors within the indium tin oxide layer (the ground electrode in a closed system) which aid in the detection of luminophores in droplets. In general, different materials may also be used to replace basic components of a DMF system such as the use of PDMS instead of glass for the substrate.
are not two constants but some random variables (a pair for each individual). This procedure has several names : "heterogeneous model", "structuration" (see also below for age structured models) or "Bayesian" view. Surprising results emerge, for instance it was proved in that the number of infected at the peak of a heterogeneous epidemic is smaller than the deterministic epidemic having same average
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.